Christopher Senner Sells 34,278 Shares of Exelixis (NASDAQ:EXEL) Stock

Exelixis, Inc. (NASDAQ:EXEL) CFO Christopher Senner sold 34,278 shares of the company’s stock in a transaction that occurred on Friday, February 13th. The shares were sold at an average price of $43.00, for a total value of $1,473,954.00. Following the completion of the sale, the chief financial officer directly owned 1,042,579 shares in the company, valued at approximately $44,830,897. The trade was a 3.18% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.

Exelixis Price Performance

Exelixis stock traded up $0.39 during mid-day trading on Wednesday, hitting $44.47. 3,267,412 shares of the company were exchanged, compared to its average volume of 2,563,792. The business’s 50 day simple moving average is $43.77 and its two-hundred day simple moving average is $41.13. The company has a market capitalization of $11.55 billion, a P/E ratio of 16.05, a PEG ratio of 0.99 and a beta of 0.42. Exelixis, Inc. has a 12-month low of $32.38 and a 12-month high of $49.62.

Exelixis (NASDAQ:EXEL) last issued its quarterly earnings data on Tuesday, February 10th. The biotechnology company reported $0.94 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.74 by $0.20. The business had revenue of $598.66 million for the quarter, compared to the consensus estimate of $609.17 million. Exelixis had a return on equity of 36.29% and a net margin of 33.73%.The business’s revenue was up 5.6% on a year-over-year basis. During the same period in the prior year, the business earned $0.55 earnings per share. Equities research analysts predict that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Institutional Inflows and Outflows

Several large investors have recently made changes to their positions in the company. Richardson Financial Services Inc. grew its position in Exelixis by 95.1% during the third quarter. Richardson Financial Services Inc. now owns 599 shares of the biotechnology company’s stock valued at $25,000 after acquiring an additional 292 shares during the period. Anchor Investment Management LLC lifted its stake in shares of Exelixis by 500.0% in the 3rd quarter. Anchor Investment Management LLC now owns 600 shares of the biotechnology company’s stock valued at $25,000 after purchasing an additional 500 shares in the last quarter. Motiv8 Investments LLC purchased a new stake in shares of Exelixis during the 4th quarter worth about $26,000. Root Financial Partners LLC acquired a new stake in Exelixis during the 3rd quarter worth approximately $28,000. Finally, Acumen Wealth Advisors LLC acquired a new stake in Exelixis during the 4th quarter worth approximately $29,000. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently commented on EXEL. UBS Group set a $41.00 price target on shares of Exelixis in a report on Monday, January 5th. Royal Bank Of Canada raised their target price on shares of Exelixis from $45.00 to $46.00 and gave the stock a “sector perform” rating in a research report on Wednesday, February 11th. Citigroup downgraded Exelixis from a “market outperform” rating to an “underperform” rating in a report on Monday, January 5th. TD Cowen reissued a “buy” rating on shares of Exelixis in a research note on Wednesday, November 5th. Finally, Wolfe Research started coverage on Exelixis in a report on Tuesday, November 18th. They set a “peer perform” rating on the stock. One equities research analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, ten have assigned a Hold rating and two have given a Sell rating to the company’s stock. According to data from MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $47.11.

Exelixis Company Profile

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.